Hanifeh Mirtavoos-Mahyari

Dr. Hanifeh Mirtavoos-Mahyari

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
KMKeywan Mortezaee
Keywan Mortezaee
ESEnsieh Salehi
Ensieh Salehi
HMHanifeh Mirtavoos-Mahyari
Hanifeh Mirtavoos-Mahyari
EMElahe Motevaseli
Elahe Motevaseli
MNMasoud Najafi
Masoud Najafi
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar

1 May 2020 in Pharmacological Research
Verified
Journal Article
Closed access
BFBagher Farhood
Bagher Farhood
EKEhsan Khodamoradi
Ehsan Khodamoradi
MHMojtaba Hoseini-Ghahfarokhi
Mojtaba Hoseini-Ghahfarokhi
EMElahe Motevaseli
Elahe Motevaseli
HMHanifeh Mirtavoos-Mahyari
Hanifeh Mirtavoos-Mahyari
MNMasoud Najafi
Masoud Najafi

22 August 2018 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
BFBagher Farhood
Bagher Farhood
NGN. H. Goradel
N. H. Goradel
KMKeywan Mortezaee
Keywan Mortezaee
NKN. Khanlarkhani
N. Khanlarkhani
ESE. Salehi
E. Salehi
MNMasoud Najafi
Masoud Najafi

1 November 2019 in International Immunopharmacology
Verified
Journal Article
Closed access
KMKeywan Mortezaee
Keywan Mortezaee
WPWrya Parwaie
Wrya Parwaie
EMElahe Motevaseli
Elahe Motevaseli
HMHanifeh Mirtavoos-Mahyari
Hanifeh Mirtavoos-Mahyari
AMAhmed Eleojo Musa
Ahmed Eleojo Musa
BFBagher Farhood
Bagher Farhood

1 December 2019 in Life Sciences
Verified
Journal Article
Closed access
KMKeywan Mortezaee
Keywan Mortezaee
YPYaiza Potes
Yaiza Potes
HMHanifeh Mirtavoos-Mahyari
Hanifeh Mirtavoos-Mahyari
EMElahe Motevaseli
Elahe Motevaseli
DSDheyauldeen Shabeeb
Dheyauldeen Shabeeb
BFBagher Farhood
Bagher Farhood

11 January 2019 in Current Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
PAPeyman Amini
Peyman Amini
HMHanifeh Mirtavoos-Mahyari
Hanifeh Mirtavoos-Mahyari
EMElahe Motevaseli
Elahe Motevaseli
DSDheyauldeen Shabeeb
Dheyauldeen Shabeeb
AMAhmed Eleojo Musa
Ahmed Eleojo Musa
MNMasoud Najafi
Masoud Najafi
Background: Melatonin is a natural body product that has shown potent antioxidant property against various toxic agents. For more than two decades, the abilities of melatonin as a potent radioprotector against toxic effects of ionizing radiation (IR) have been proved. However, in the recent years, several studies have been conducted to illustrate how melatonin protects normal cells against IR. Studies proposed that melatonin is able to directly neutralize free radicals produced by IR, leading to the production of some low toxic products.Discussion: Moreover, melatonin affects several signaling pathways, such as inflammatory responses, antioxidant defense, DNA repair response enzymes, pro-oxidant enzymes etc. Animal studies have confirmed that melatonin is able to alleviate radiation-induced cell death via inhibiting pro-apoptosis and upregulation of anti-apoptosis genes. These properties are very interesting for clinical radiotherapy applications, as well as mitigation of radiation injury in a possible radiation disaster. An interesting property of melatonin is mitochondrial ROS targeting that has been proposed as a strategy for mitigating effects in radiosensitive organs, such as bone marrow, gastrointestinal system and lungs. However, there is a need to prove the mitigatory effects of melatonin in experimental studies.Conclusion: In this review, we aim to clarify the molecular mechanisms of radioprotective effects of melatonin, as well as possible applications as a radiation countermeasure in accidental exposure or nuclear/radiological disasters.